Novo Nordisk said the heart-protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday.Early data from the Danish drugmaker’s Select trial released in August demonstrated that Wegovy, which has been shown to help patients lose an average of 15 per cent of their weight, also reduced the incidence of heart attack, stroke or death from heart disease by 20 per cent.
Full results from the study, presented at the American Heart Association annual scientific meeting in Philadelphia in front of a standing-room-only crowd and published in the New England Journal of Medicine, suggest the drug has other beneficial effects beyond the known health benefits from losing weight.